New research published in Value in Health's February 2019 edition suggests there exists no standardized method to measure multiple medication adherence (MMA), nor agreement among researchers on a measure to calculate it. According to a press release, the team of researchers reviewed 147 studies […]
Latest Stories
Podcast Spotlights Chargemasters
A new Relentless Health Value featuring Luna Healthcare Advisors Founder and Principal Caroline Znaniec in a discussion about chargemasters. Znaniec offers up some advice that could help hospitals tackle some of the issues involved with the new price lists. Click here to listen to the podcast. […]
ISPOR Issues Call for Reviewers for Latin America Conference
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) has issued a call for reviewers among its members for its Sept. 12-14 ISPOR Latin America 2019 conference in Bogotá, Colombia. The deadline to apply, according to an email, is Thursday, Feb. 28. Volunteers will review […]
Study: Interest in VBCs Greater Than Previously Thought
A recent survey conducted by the Duke University Robert J. Margolis, MD, Center for Health Policy and the National Pharmaceutical Council suggests that interest in value-based contracts may have been greater than previously thought. The study, which was published in the American Journal of Managed […]
UnitedHealthCare Seeks 21-Month Notice for Drug Price Hikes
In response to recent movements by drugmakers to decrease prices to save on rebates, UnitedHealthCare is demanding from pharmaceutical companies notice of price reductions seven quarters in advance, FiercePharma reports. According to the report, the request for such long-term notice is for drugs […]
Once-Free Drug to Cost $300,000-plus Per Year
Catalyst Pharmaceuticals' Firdapse, which is used to treat Lambert-Eaton Myasthenic Syndrome, will hit the market with a list price of $375,000 per year, Reuters reports. The drugmaker announced the price, which excludes discounts and rebates, on Monday. It told investors in New York on Monday that […]
Value Communication is Not Fit for Purpose in Biopharma
From tHEORetically Speaking Value communication (VC) is essential for a successful market access strategy that aims to bring interventions to patients. It is no longer enough to simply show that an intervention is effective. VC must also focus on health economics and outcomes research (HEOR), […]
Efforts to Bolster PROs Expected to Play Key Role in Cancer Drug Development
New efforts by regulators and organizations to help fill information gaps in patient-reported outcomes could play a key role in advancing cancer drug development, according to a Cancer Therapy Advisor report. Ethan Basch, University of North Carolina-Chapel Hill professor of medicine and director […]
Article: Price Drops on Praluent, Repatha Boon for Patients
Regeneron and Sanofi's recent decision to lower the list price on their cholesterol-lowering injection Repatha could be seen as "the final surrender" to the market for anti-PCSK9 antibodies, according to a recent article published on Evaluate. The drugmakers lowered the price to $5,850, which is […]
AMCP Spotlights Recent Managed Care News
The Academy of Managed Care Pharmacy in its weekly podcast, Managed Care Cast, posted Feb. 10 highlights some of the recent happenings in health care. The podcast delves into President Donald Trump's second State of the Union address, which included an update on the health care industry, as well as […]
